An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies

Trial Profile

An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Roniciclib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 27 Apr 2018 to 26 Apr 2019.
    • 08 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 24 Mar 2016 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top